Search
Mecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalIn 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency[F4075]. … Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722].
Chlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]
Dicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigational[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967] … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.
Teprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigational[L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was … approved by the FDA in January 2020 for the treatment of TED.
rhThrombin
go.drugbank.com/drugs/DB04923ApprovedWithdrawnThrombin is used in more than 1 million surgeries each year in the United States. Currently, only thrombin derived from bovine blood is available in the U.S. as a stand-alone thrombin product. … The production of recombinant proteins is not dependent on the availability of blood from animals or human donors and can be scaled-up to meet market demand.
Tiagabine
go.drugbank.com/drugs/DB00906ApprovedTiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. … Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Ifosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIt is active as an alkylating agent and an immunosuppressive agent.
Products: IFO-CELL N 1000, IFO-cell N 1000; Solution for Infusion (1000mg per vial)Tenocyclidine
go.drugbank.com/drugs/DB01520IllicitInvestigationalIt is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Categories: Compounds used in a research, industrial, or household settingLevonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.